Current Report Filing (8-k)
December 09 2021 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): December 8, 2021
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
ONCS
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.01
|
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On
November 29, 2021, OncoSec Medical Incorporated (the “Company”) notified The Nasdaq Capital Market (“Nasdaq”)
that Robert E. Ward, as previously disclosed on the Company’s Current Report filed on Form 8-K on November 30, 2021, had resigned
as a member of the Board of Directors and the Company’s Audit Committee. After giving effect to Mr. Ward’s resignation, the
Company’s Audit Committee no longer consists of three independent members as required by Nasdaq Listing Rule 5605(c)(2)(A).
On
December 8, 2021, the Company received a letter from Nasdaq noting that the Company no longer complied with the requirement of Listing
Rule 5605. The letter also acknowledged that the Listing Rules provide a cure period in order for the Company to regain compliance until
the earlier of the Company’s next annual meeting of stockholders or November 23, 2022 (or, by May 23, 2022, if such meeting is
held before May 23, 2022).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED
|
|
(Registrant)
|
|
|
|
Date: December 9, 2021
|
|
|
|
|
|
|
By:
|
/s/
Dr. Margaret Dalesandro
|
|
Name:
|
Dr.
Margaret Dalesandro
|
|
Title:
|
Interim
Principal Executive Officer and Chair of the Board
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024